DSDominik Schum

Dominik Schum

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dominik Schum has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Decoding antibiotic modes of action from multimodal cellular responses

    by Joshua Hesse, Dominik Schum, Laura Leidel, Leonard R. Gareis, Jennifer Herrmann, Rolf Müller, Stephan A. Sieber

    Antibiotic resistance continues to rise, yet most new drug candidates act through long-established targets. Faster mode of action (MoA) assessment would enable more effective prioritization of screening hits and help identify compounds with novel mechanisms. In this study, we aimed to develop a scalable framework for MoA inference from antibiotic-induced cellular response profiles in Escherichia coli . We generated a multimodal dataset spanning more than 50 antibiotics, including proteome profiles, chemical structure descriptors, inhibitory concentrations and growth dynamics, and used it to build MAPPER (Mode of Action Prediction via Proteomics-Enhanced Representation), a framework comprising a fixed multimodal predictor and an uncertainty module. MAPPER accurately classified antibiotics across nine mechanistic classes, flagged compounds with likely novel mechanisms and retained predictive power in proteomics-only transfer experiments across mass spectrometry platforms and external data. Together, these results establish MAPPER as an innovative tool for MoA prediction and novelty detection, enabling prioritization of antibacterial candidates with distinct mechanisms.

  • Open Access

    Generative Deep Learning Pipeline Yields Potent Gram-Negative Antibiotics

    by Martin F. Köllen, Maximilian G. Schuh, Robin Kretschmer, Joshua Hesse, Dominik Schum, Junhong Chen, Annkathrin I. Bohne, Dominik P. Halter, Stephan A. Sieber

    The escalating crisis of multiresistant bacteria demands the rapid discovery of novel antibiotics that transcend the limitations imposed by the biased chemical space of current libraries. To address this challenge, we introduce an innovative deep learning-driven pipeline for de novo antibiotic design. Our unique approach leverages a chemical language model to generate structurally unprecedented antibiotic candidates. The model was trained on a diverse chemical space of drug-like molecules and natural products. We then applied transfer learning using a data set of diverse antibiotic scaffolds to refine its generative capabilities. Using predictive modeling and expert curation, we prioritized the most promising compounds for synthesis. This pipeline identified a lead candidate with potent activity against methicillin-resistant Staphylococcus aureus. We then performed iterative refinement by synthesizing 40 derivatives of the lead compound. This effort produced a suite of active compounds, with 30 showing activity against S. aureus and 17 against Escherichia coli. Among these, lead compound D8 exhibited remarkable submicromolar and single-digit micromolar potency against the aforementioned pathogens, respectively. Mechanistic investigations point to the reductive generation of reactive species as its primary mode of action. This work validates a deep-learning pipeline that explores chemical space to generate antibiotic candidates. This process yields a potent nitrofuran derivative and a set of experimentally validated scaffolds to seed future antibiotic development.


  • Open Access

    Screening Privileged Alkyl Guanidinium Motifs under Host-Mimicking Conditions Reveals a Novel Antibiotic with an Unconventional Mode of Action

    by Dominik Schum, Franziska A. V. Elsen, Stuart Ruddell, Kenji Schorpp, Howard Junca, Mathias Müsken, Shu-Yu Chen, Michaela K. Fiedler, Thomas Pickl, Dietmar H. Pieper, et al.

    Screening large molecule libraries against pathogenic bacteria is often challenged by a low hit rate due to limited uptake, underrepresentation of antibiotic structural motifs, and assays that do not resemble the infection conditions. To address these limitations, we present a screen of a focused library of alkyl guanidinium compounds, a structural motif associated with antibiotic activity and enhanced uptake, under host-mimicking infection conditions against a panel of disease-associated bacteria. Several hit molecules were identified with activities against Gram-positive and Gram-negative bacteria, highlighting the fidelity of the general concept. We selected one compound (L15) for in-depth mode of action studies that exhibited bactericidal activity against methicillin-resistant Staphylococcus aureus USA300 with a minimum inhibitory concentration of 1.5 μM. Structure-activity relationship studies confirmed the necessity of the guanidinium motif for antibiotic activity. The mode of action was investigated using affinity-based protein profiling with an L15 probe and identified the signal peptidase IB (SpsB) as the most promising hit. Validation by activity assays, binding site identification, docking, and molecular dynamics simulations demonstrated SpsB activation by L15, a recently described mechanism leading to the dysregulation of protein secretion and cell death. Overall, this study highlights the need for unconventional screening strategies to identify novel antibiotics.


  • Open Access

    Bacillamide D produced by Bacillus cereus from the mouse intestinal bacterial collection (miBC) is a potent cytotoxin in vitro

    by Maximilian Hohmann, Valentina Brunner, Widya Johannes, Dominik Schum, Laura M. Carroll, Tianzhe Liu, Daisuke Sasaki, Johanna Bosch, Thomas Clavel, Stephan A. Sieber, et al.

    The gut microbiota influences human health and the development of chronic diseases. However, our understanding of potentially protective or harmful microbe-host interactions at the molecular level is still in its infancy. To gain further insights into the hidden gut metabolome and its impact, we identified a cryptic non-ribosomal peptide BGC in the genome of Bacillus cereus DSM 28590 from the mouse intestine (www.dsmz.de/miBC), which was predicted to encode a thiazol(in)e substructure. Cloning and heterologous expression of this BGC revealed that it produces bacillamide D. In-depth functional evaluation showed potent cytotoxicity and inhibition of cell migration using the human cell lines HCT116 and HEK293, which was validated using primary mouse organoids. This work establishes the bacillamides as selective cytotoxins from a bacterial gut isolate that affect mammalian cells. Our targeted structure-function-predictive approach is demonstrated to be a streamlined method to discover deleterious gut microbial metabolites with potential effects on human health.